Drugs / IN01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04537130 | Dec 2020 → Jun 2021 | COVID-19, pulmonary fibrosis | Instituto Oncológico Dr Rosell | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537130 ↗ |
| Action | Inhibit | “The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor...” NCT04537130 ↗ |
| Modality | Vaccine | “IN01 vaccine” NCT04537130 ↗ |
| Target | EGF | “The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor...” NCT04537130 ↗ |